Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial-Reference-Cited by-同舟云学术

Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Published:2021-05 Issue: Volume:149 Page:14-22
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tanaka Kentaro,Asahina Hajime^ORCID,Kishimoto Junji,Miyata Yoshihiro,Uchida Takahiro,Watanabe Kana,Hamai Kosuke^ORCID,Harada Taishi,Tsubata Yukari^ORCID,Sugawara Shunichi^ORCID,Kobayashi Kunihiko,Sugio Kenji,Oizumi Satoshi,Okamoto Isamu

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Canc Discov,2014

2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Janne;N Engl J Med,2015

3. Osimertinib or platinum-pemetrexed in EGFR t790m-positive lung cancer;Mok;N Engl J Med,2017

4. Mechanisms of osimertinib resistance and emerging treatment options;Schmid;Lung Canc,2020

5. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review;Piper-Vallillo;J Clin Oncol,2020

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of a bioinformatics-based prognostic model related to liquid-liquid phase separation in lung adenocarcinoma;2024-01-10

2. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study;Annals of Oncology;2024-01

3. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies;Exploration of Targeted Anti-tumor Therapy;2023-10-10

4. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation;American Journal of Clinical Oncology;2023-10-02

5. Neoadjuvant therapy in non-small cell lung cancer;Critical Reviews in Oncology/Hematology;2023-10